A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

Before GLP-1 agonists became the blockbuster obesity ... obesity would be the first for this drug in an acquired form of obesity. It could also potentially become the first approved treatment ...

While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development ... can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S.

Northstrive Biosciences and Yuva Biosciences' collaboration will leverage MitoNova™, YuvaBio's proprietary mitochondrial ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...